{"product_id":"mt-2-melanotan-2-acetate-10mg","title":"MT-II (Melanotan II Acetate) 10mg","description":"\u003ch2\u003eMelanotan II (MT-II) Overview\u003c\/h2\u003e\n\u003cp class=\"\"\u003eMelanotan II (MT-II) is a \u003cstrong\u003esynthetic, cyclic peptide\u003c\/strong\u003e developed as an analogue of \u003cstrong\u003eα-melanocyte-stimulating hormone (α-MSH)\u003c\/strong\u003e. It works as a \u003cstrong\u003enon-selective melanocortin receptor agonist\u003c\/strong\u003e, meaning it can activate multiple melanocortin receptors involved in pigmentation and other physiologic effects. (\u003ca href=\"https:\/\/peptidesociety.org\/wp-content\/uploads\/2018\/05\/Melanotan-II-monograph-v2.docx.pdf?utm_source=chatgpt.com\" title=\"Professional Monograph Melanotan II\"\u003eThe International Peptide Society\u003c\/a\u003e)\u003c\/p\u003e\n\u003cp class=\"\"\u003eMT-II is best known for its ability to stimulate \u003cstrong\u003emelanin production (tanning)\u003c\/strong\u003e in humans, but it is also associated with a range of systemic side effects and safety concerns, especially when used via unregulated products. (\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/?utm_source=chatgpt.com\" title=\"Evaluation of melanotan-II, a superpotent cyclic melanotropic ...\"\u003ePubMed\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003ePigmentation and “Tanning” Effects\u003c\/h2\u003e\n\u003ch3\u003eIncreases melanin production and visible pigmentation\u003c\/h3\u003e\n\u003cp class=\"\"\u003eEarly clinical pharmacology research demonstrated that MT-II can produce \u003cstrong\u003etanning activity in humans\u003c\/strong\u003e after a limited number of subcutaneous doses in controlled research conditions. (\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/?utm_source=chatgpt.com\" title=\"Evaluation of melanotan-II, a superpotent cyclic melanotropic ...\"\u003ePubMed\u003c\/a\u003e)\u003c\/p\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eImportant context:\u003c\/strong\u003e demonstrating tanning activity is not the same as proving long-term safety—particularly for products sold outside regulated clinical manufacturing and medical supervision. (\u003ca href=\"https:\/\/dermnetnz.org\/topics\/melanotan-ii?utm_source=chatgpt.com\" title=\"Melanotan II\"\u003eDermNet®\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp class=\"\"\u003eMT-II is described in the scientific literature as a \u003cstrong\u003emelanocortin receptor agonist\u003c\/strong\u003e (often discussed across MC1R\/MC3R\/MC4R\/MC5R activity). Pigmentation is primarily linked to melanocortin signaling in the skin (classically MC1R), while other receptor activity is associated with non-pigment effects (e.g., appetite\/sexual side effects discussed in reports). (\u003ca href=\"https:\/\/peptidesociety.org\/wp-content\/uploads\/2018\/05\/Melanotan-II-monograph-v2.docx.pdf?utm_source=chatgpt.com\" title=\"Professional Monograph Melanotan II\"\u003eThe International Peptide Society\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eSafety, Adverse Effects, and Regulatory Concerns\u003c\/h2\u003e\n\u003ch3\u003eCommonly reported short-term effects\u003c\/h3\u003e\n\u003cp class=\"\"\u003eMedical dermatology references describe short-term effects such as \u003cstrong\u003enausea, flushing, reduced appetite\u003c\/strong\u003e, and (in males) \u003cstrong\u003espontaneous erections\u003c\/strong\u003e, with concern for prolonged erections\/priapism. (\u003ca href=\"https:\/\/dermnetnz.org\/topics\/melanotan-ii?utm_source=chatgpt.com\" title=\"Melanotan II\"\u003eDermNet®\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003eSerious adverse event reports (case literature)\u003c\/h3\u003e\n\u003cp class=\"\"\u003ePeer-reviewed case reports and reviews describe serious events temporally associated with MT-II use, including \u003cstrong\u003eischemic priapism\u003c\/strong\u003e and \u003cstrong\u003erenal infarction\/kidney injury\u003c\/strong\u003e. (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6388891\/?utm_source=chatgpt.com\" title=\"Melanotan-induced priapism: a hard-earned tan - PMC\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003eSkin lesion changes and melanoma concern\u003c\/h3\u003e\n\u003cp class=\"\"\u003eDermatology sources warn about \u003cstrong\u003enew or changing moles, darkening lesions, and melanoma concern\u003c\/strong\u003e, particularly given melanocortin stimulation combined with UV exposure behaviors that often accompany “tanning” use. (\u003ca href=\"https:\/\/dermnetnz.org\/topics\/melanotan-ii?utm_source=chatgpt.com\" title=\"Melanotan II\"\u003eDermNet®\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003ePublic health warnings about unregulated products\u003c\/h3\u003e\n\u003cp class=\"\"\u003eRegulators and clinical organizations have issued safety communications warning against melanotan products due to reported adverse effects, product variability\/contamination risk, and potential long-term harms. (\u003ca href=\"https:\/\/www.tga.gov.au\/news\/blog\/dont-risk-using-tanning-products-containing-melanotan?utm_source=chatgpt.com\" title=\"Don't risk using tanning products containing melanotan\"\u003eTherapeutic Goods Administration (TGA)\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch3\u003eNot FDA-approved \/ enforcement history\u003c\/h3\u003e\n\u003cp class=\"\"\u003eFDA records document concerns with marketing Melanotan II (MII) as an unapproved “new drug” without an approved application, reflecting the regulatory status and enforcement posture toward such products. (\u003ca href=\"https:\/\/www.fda.gov\/media\/128834\/download?utm_source=chatgpt.com\" title=\"Edward Manookian Docket No. FDA-2015-N-4169 Page 2\"\u003eU.S. Food and Drug Administration\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eMelanotan II Specifications\u003c\/h2\u003e\n\u003cp class=\"\"\u003eFrom NIH PubChem and FDA’s GInAS entry for the substance:\u003c\/p\u003e\n\u003cul data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 121062-08-6 (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II?utm_source=chatgpt.com\" title=\"melanotan-II | C50H69N15O9 | CID 92432 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₅₀H₆₉N₁₅O₉ (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II?utm_source=chatgpt.com\" title=\"melanotan-II | C50H69N15O9 | CID 92432 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e ~1024.2 g\/mol (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II?utm_source=chatgpt.com\" title=\"melanotan-II | C50H69N15O9 | CID 92432 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003e\u003cstrong\u003ePeptide type:\u003c\/strong\u003e cyclic melanocortin analogue \/ melanocortin receptor agonist (\u003ca href=\"https:\/\/peptidesociety.org\/wp-content\/uploads\/2018\/05\/Melanotan-II-monograph-v2.docx.pdf?utm_source=chatgpt.com\" title=\"Professional Monograph Melanotan II\"\u003eThe International Peptide Society\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\"\u003e\u003cem\u003e(Note: supplier listings sometimes also reference salt forms such as acetate, which can differ in formula\/mass.)\u003c\/em\u003e(\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Melanotan-II-acetate?utm_source=chatgpt.com\" title=\"Melanotan II acetate | C52H73N15O11 - PubChem - NIH\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch2\u003eImportant Notice\u003c\/h2\u003e\n\u003cp class=\"\"\u003eMelanotan II is \u003cstrong\u003enot an FDA-approved medication\u003c\/strong\u003e for cosmetic tanning, and it is frequently encountered in \u003cstrong\u003eunregulated products\u003c\/strong\u003e (injections, nasal sprays, etc.) with significant safety concerns. Any description intended for commerce should remain consistent with \u003cstrong\u003ein vitro research-only\u003c\/strong\u003e positioning and should not present MT-II as a drug, supplement, cosmetic, or food product. (\u003ca href=\"https:\/\/www.fda.gov\/media\/128834\/download?utm_source=chatgpt.com\" title=\"Edward Manookian Docket No. FDA-2015-N-4169 Page 2\"\u003eU.S. Food and Drug Administration\u003c\/a\u003e)\u003c\/p\u003e\n\u003ch1\u003eReferences\u003c\/h1\u003e\n\u003col data-rte-list=\"default\"\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eDorr RT, et al. \u003cstrong\u003eEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in humans (tanning activity).\u003c\/strong\u003e \u003cem\u003ePubMed record\u003c\/em\u003e (1996). (\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/?utm_source=chatgpt.com\" title=\"Evaluation of melanotan-II, a superpotent cyclic melanotropic ...\"\u003ePubMed\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eDermNet NZ. \u003cstrong\u003eMelanotan II (side effects; mole changes; melanoma concern; rhabdomyolysis\/encephalopathy warnings).\u003c\/strong\u003e (\u003ca href=\"https:\/\/dermnetnz.org\/topics\/melanotan-ii?utm_source=chatgpt.com\" title=\"Melanotan II\"\u003eDermNet®\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eTherapeutic Goods Administration (Australia). \u003cstrong\u003eDon’t risk using tanning products containing melanotan\u003c\/strong\u003e (Jan 24, 2025). (\u003ca href=\"https:\/\/www.tga.gov.au\/news\/blog\/dont-risk-using-tanning-products-containing-melanotan?utm_source=chatgpt.com\" title=\"Don't risk using tanning products containing melanotan\"\u003eTherapeutic Goods Administration (TGA)\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eHealth Products Regulatory Authority (Ireland). \u003cstrong\u003eReminder of serious health risks with Melanotan 2 self-tan products\u003c\/strong\u003e (Aug 10, 2023). (\u003ca href=\"https:\/\/www.hpra.ie\/safety-information\/safety-notices\/article\/reminder-of-serious-health-risks-with-melanotan-2-self-tan-products?utm_source=chatgpt.com\" title=\"Reminder of serious health risks with Melanotan 2 self-tan ...\"\u003eHPRA\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003ePeters B, et al. \u003cstrong\u003eMelanotan II: possible cause of renal infarction\u003c\/strong\u003e (case report\/review). \u003cem\u003eBMJ Case Reports \/ PMC\u003c\/em\u003e(2020). (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7148395\/?utm_source=chatgpt.com\" title=\"Melanotan II: a possible cause of renal infarction\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eDreyer BA, et al. \u003cstrong\u003eMelanotan-induced priapism\u003c\/strong\u003e (case report). \u003cem\u003eBMJ Case Reports \/ PMC\u003c\/em\u003e (2019). (\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6388891\/?utm_source=chatgpt.com\" title=\"Melanotan-induced priapism: a hard-earned tan - PMC\"\u003ePMC\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eMallory CW, et al. \u003cstrong\u003eMelanotan tanning injection: a rare cause of priapism\u003c\/strong\u003e (case report). \u003cem\u003eUrology Case Reports\u003c\/em\u003e(2021). (\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2050116120301859?utm_source=chatgpt.com\" title=\"Melanotan Tanning Injection: A Rare Cause of Priapism\"\u003eScienceDirect\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eFDA docket document referencing FDA warning letter concerns about marketing MII as an unapproved new drug. (\u003ca href=\"https:\/\/www.fda.gov\/media\/128834\/download?utm_source=chatgpt.com\" title=\"Edward Manookian Docket No. FDA-2015-N-4169 Page 2\"\u003eU.S. Food and Drug Administration\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eNIH PubChem. \u003cstrong\u003eMelanotan II compound record (CAS, formula, molecular weight).\u003c\/strong\u003e (\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II?utm_source=chatgpt.com\" title=\"melanotan-II | C50H69N15O9 | CID 92432 - PubChem\"\u003ePubChem\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"\"\u003eFDA GInAS substance entry. \u003cstrong\u003eMELANOTAN II (formula and molecular weight).\u003c\/strong\u003e (\u003ca href=\"https:\/\/precision.fda.gov\/ginas\/app\/ui\/substances\/ea753edd-ab89-4212-8f75-d704ff9b05e3?utm_source=chatgpt.com\" title=\"MELANOTAN II\"\u003eprecision.fda.gov\u003c\/a\u003e)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003e\u003cstrong\u003eComplete Disclaimer\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\"\u003eThis product is sold exclusively for laboratory research purposes under Section 351 of the Public Health Service Act. It is not intended for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic applications. Purchaser certifies they are properly licensed and equipped to handle research compounds in compliance with all local, state, and federal regulations. EaglePeptidesUSA assumes no liability for misuse or unauthorized handling. By purchasing, you affirm this material will not be introduced into interstate commerce or used in food\/drug products.\u003c\/p\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":53220095918444,"sku":null,"price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1539\/6716\/files\/MT-2_EAGLE_USABackgroundRemoved.png?v=1772478062","url":"https:\/\/eaglepeptidesusa.com\/products\/mt-2-melanotan-2-acetate-10mg","provider":"My Store","version":"1.0","type":"link"}